BMO Capital Reiterates Outperform Rating on Amgen (AMGN)

July 1, 2026 8:48 AM EDT Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $400.00 price target on Amgen (NASDAQ: AMGN).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login